197 related articles for article (PubMed ID: 11215116)
1. [Molecular mechanism of bone metabolism].
Kotake S; Utagawa N; Suda T; Kamatani N
Nihon Naika Gakkai Zasshi; 2000 Oct; 89(10):2046-53. PubMed ID: 11215116
[No Abstract] [Full Text] [Related]
2. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
3. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
Ferrer Cañabate J; Tovar I; Martínez P
An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
[No Abstract] [Full Text] [Related]
4. [Recent advance in basic research for osteoporosis].
Suda T; Miyaura C
Nihon Rinsho; 2004 Feb; 62 Suppl 2():13-20. PubMed ID: 15035090
[No Abstract] [Full Text] [Related]
5. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
[TBL] [Abstract][Full Text] [Related]
6. [Merger of bone biology and immunology].
Suda T; Shima N; Higashio K
Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
[No Abstract] [Full Text] [Related]
7. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
Hofbauer LC; Heufelder AE; Erben RG
J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
[No Abstract] [Full Text] [Related]
8. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
Kong YY; Feige U; Sarosi I; Bolon B; Tafuri A; Morony S; Capparelli C; Li J; Elliott R; McCabe S; Wong T; Campagnuolo G; Moran E; Bogoch ER; Van G; Nguyen LT; Ohashi PS; Lacey DL; Fish E; Boyle WJ; Penninger JM
Nature; 1999 Nov; 402(6759):304-9. PubMed ID: 10580503
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
10. [Osteoporosis].
Chaki O
Nihon Rinsho; 2006 Apr; 64 Suppl 4():370-4. PubMed ID: 16689336
[No Abstract] [Full Text] [Related]
11. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
12. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
Cozzani M; Giovannini I; Naccari R; Penolazzi L; Lambertini E; Borgatti M; Piva R; Gambari R; Siciliani G
Prog Orthod; 2005; 6(2):238-47. PubMed ID: 16276433
[No Abstract] [Full Text] [Related]
13. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
Kostenuik PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
[TBL] [Abstract][Full Text] [Related]
15. [Osteoclast-activating factors (OAF)].
Sato K
Nihon Rinsho; 2004 Dec; 62 Suppl 12():228-31. PubMed ID: 15658306
[No Abstract] [Full Text] [Related]
16. RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro.
Frick KK; LaPlante K; Bushinsky DA
Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1005-11. PubMed ID: 15972386
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
Blair JM; Zhou H; Seibel MJ; Dunstan CR
Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
Hofbauer LC
Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
[No Abstract] [Full Text] [Related]
19. Evidence of a role for RANKL in the development of myeloma bone disease.
De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
[TBL] [Abstract][Full Text] [Related]
20. Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics.
Zaidi M; Blair HC; Moonga BS; Abe E; Huang CL
J Bone Miner Res; 2003 Apr; 18(4):599-609. PubMed ID: 12674320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]